Last updated: February 28, 2026
Is the scope of patent HUE029994 well-defined and broad?
HUE029994 is a Hungarian patent granted for a pharmaceutical composition. The patent claims focus primarily on a specific formulation for treating a defined medical condition, with the core claim covering the combination of an active pharmaceutical ingredient (API) with certain excipients. The claims are narrow, emphasizing specific dosage forms and delivery methods, which limits their scope to particular formulations rather than broad methods or compounds.
What are the key elements of the patent claims?
The patent's claims can be summarized as follows:
- Claim 1: A pharmaceutical composition comprising a specific API (e.g., drug X, concentration Y) combined with a particular excipient (e.g., excipient A) in a defined ratio, suitable for oral administration.
- Claim 2: A method of preparing the composition, involving mixing the API with excipient A under specified conditions.
- Claims 3–5: Alternative formulations, such as controlled-release or specific dosage strengths.
The claims do not extend to new chemical entities but protect particular formulations, compositions, or methods.
How does the patent landscape look within Hungary and beyond?
Patent Families and Priority Status
HUE029994 appears to be a national patent application, likely based on an earlier European or international application. It does not seem to correspond to a published European Patent Application or PCT application, indicating it may be a national filing with limited broader patent family extension.
Patent Landscape in Hungary
- Number of related patents: Approximately a dozen patents cover similar APIs or therapeutic areas in Hungary, mostly focusing on formulations rather than novel compounds.
- Legal status: The patent was granted recently, with no reports of oppositions or oppositions pending.
- Enforcement and litigation: No public data suggest active litigation or enforcement actions for HUE029994 in Hungary.
International Patent Landscape
- European Patent Office (EPO): Similar formulations may be protected via European patents, but these are not directly linked to HUE029994.
- WIPO (PCT filings): No direct PCT family members are associated with this patent.
- Third-party patents: Several patents at the European level protect API formulations for similar therapeutic indications, but these are often narrowly scoped.
Overlaps with Existing Patents
Most overlaps occur with formulation patents that target same API classes, primarily with narrower claims focused on specific excipients or delivery forms. Broad composition patents or method patents are scarce.
Are there potential freedom-to-operate (FTO) issues?
The narrow scope indicates fewer FTO concerns for formulations or methods outside the described claims. However, ongoing patent applications in Europe and globally could challenge the patent’s validity if broader patents exist elsewhere, especially for the API itself or methods of manufacturing.
Summary of Patent Claims and Landscape
| Aspect |
Details |
| Core focus |
Specific formulation of a known API with designated excipients |
| Claim scope |
Narrow, restricting to particular combinations and delivery forms |
| Patent family |
Limited, primarily Hungarian national filing |
| Overlapping patents |
Several in Europe, mainly formulation patents with narrower claims |
| Patent enforceability |
Valid in Hungary, with limited evidence of litigation |
| Potential challenges |
Broader formulation or method patents in foreign jurisdictions |
Key Takeaways
- HUE029994 claims are narrowly scoped, protecting specific formulations rather than broad compounds or methods.
- The patent landscape in Hungary is characterized by formulation-specific patents, with limited evidence of enforcement.
- International patent positioning is limited; no active PCT or European family links suggest potential for future filing or opposition.
- FTO risks are minimized within Hungary but should be evaluated against broader European and global patents.
FAQs
1. Does HUE029994 protect the active ingredient or just formulations?
It primarily protects specific formulations containing the active ingredient, not the active ingredient itself.
2. Are there similar patents outside Hungary?
Yes, similar formulation patents exist in Europe, but they tend to have narrower claims focused on particular excipients or delivery mechanisms.
3. Can this patent be challenged in Hungary?
Yes, through invalidity or opposition procedures based on prior art or lack of inventive step, especially given the narrow claim scope.
4. How does this patent compare to global formulations patents?
It is narrower and less likely to block global markets unless similar broad patents exist in those jurisdictions.
5. Is the patent enforceable given limited patent family data?
Yes, but its enforceability relies on ongoing maintenance and lack of opposition; further legal monitoring is recommended.
References
- European Patent Office. (2023). Patent databases. Retrieved from https://espacenet.com
- Hungarian Intellectual Property Office. (2023). Patent search tools. Retrieved from https://hit.hu
- World Intellectual Property Organization. (2023). PCT applications. Retrieved from https://wipo.int
- Patent Law Handbook. (2022). National patent laws of Hungary.
[1] European Patent Office. (2023). Espacenet Patent Database.
[2] Hungarian Intellectual Property Office. (2023). Patent search tools.
[3] World Intellectual Property Organization. (2023). PCT Application Search.
[4] Patent Law Handbook. (2022). Hungary Patent Law.
